Skip to Content

New Drug Approvals Archive - December 2020

See also: New Indications and Dosage Forms for December 2020

December 2020

Ga 68 PSMA-11 () Injection

Date of Approval: December 1, 2020
Company: University of California, San Francisco
Treatment for: Diagnostic

Ga 68 PSMA-11 Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.

Orladeyo (berotralstat) Capsules

Date of Approval: December 3, 2020
Company: BioCryst Pharmaceuticals, Inc.
Treatment for: Hereditary Angioedema

Orladeyo (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

Klisyri (tirbanibulin) Ointment

Date of Approval: December 14, 2020
Company: Athenex, Inc.
Treatment for: Actinic Keratosis

Klisyri (tirbanibulin) is a first-in-class dual Src Kinase and tubulin polymerization inhibitor for the topical treatment of actinic keratosis on the face or scalp.

Margenza (margetuximab-cmkb) Injection

Date of Approval: December 16, 2020
Company: MacroGenics, Inc.
Treatment for: Breast Cancer

Margenza (margetuximab-cmkb) is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2- positive breast cancer.

Riabni (rituximab-arrx) Injection

Date of Approval: December 17, 2020
Company: Amgen
Treatment for: non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Wegener's Granulomatosis, Microscopic Polyangiitis

Riabni (rituximab-arrx) is a CD20-directed cytolytic antibody biosimilar to Rituxan indicated for the treatment of adult patients with non-Hodgkin’s Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) (Wegener’s Granulomatosis) and microscopic polyangiitis (MPA).

Orgovyx (relugolix) Tablets

Date of Approval: December 18, 2020
Company: Myovant Sciences
Treatment for: Prostate Cancer

Orgovyx (relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.

Ebanga (ansuvimab-zykl) Injection

Date of Approval: December 21, 2020
Company: Ridgeback Biotherapeutics, LP.
Treatment for: Zaire Ebolavirus Infection

Ebanga (ansuvimab-zykl) is a monoclonal antibody for the treatment of Zaire ebolavirus (Ebolavirus) infection in adults and children.

Gemtesa (vibegron) Tablets

Date of Approval: December 23, 2020
Company: Urovant Sciences
Treatment for: Overactive Bladder Syndrome

Gemtesa (vibegron) is a once-daily beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.

New Drug Approvals Archive

2020
January, February, March, April, May, June, July, August, September, October, November, December
2019
January, February, March, April, May, June, July, August, September, October, November, December
2018
January, February, March, April, May, June, July, August, September, October, November, December
2017
January, February, March, April, May, June, July, August, September, October, November, December
2016
January, February, March, April, May, June, July, August, September, October, November, December
2015
January, February, March, April, May, June, July, August, September, October, November, December
2014
January, February, March, April, May, June, July, August, September, October, November, December
2013
January, February, March, April, May, June, July, August, September, October, November, December
2012
January, February, March, April, May, June, July, August, September, October, November, December
2011
January, February, March, April, May, June, July, August, October, November, December
2010
January, February, March, April, May, June, July, August, September, October, November, December
2009
January, February, March, April, May, June, July, August, September, October, November, December
2008
January, February, March, April, May, June, July, August, September, October, November, December
2007
January, February, March, April, May, June, July, August, September, October, November, December
2006
January, February, March, April, May, June, July, August, September, October, November, December
2005
January, February, March, April, May, June, July, August, September, October, November, December
2004
January, February, March, April, May, June, July, August, September, October, November, December
2003
January, February, March, April, May, June, July, August, September, October, November, December
2002
January, February, April, May, July, August, October, November, December

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.